- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04899141
Prospective Registry of ihtDEStiny® Coronary Stent in Regular PCI Practice (VELAZQUEZ)
January 7, 2024 updated by: Fundación EPIC
Prospective registry intended to evaluate clinical outcomes of ihtDEStiny drug eluting coronary stent.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Prospective registry intended to evaluate clinical outcomes of ihtDEStiny drug eluting coronary stent use in real-world percutaneous coronary intervention
Study Type
Observational
Enrollment (Actual)
400
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: FUNDACION EPIC
- Phone Number: 6 0034987876135
- Email: iepic@fundacionepic.org
Study Contact Backup
- Name: JOSE ANTONIO LINARES VICENTE, MD,PhD
- Email: jalinares@asociacionepic.org
Study Locations
-
-
-
Faro, Portugal, 8000-386
- Centro Hospitalar Universitario Do Algarbe
-
-
-
-
-
Barakaldo, Spain, 48903
- Hospital Universitario de Cruces
-
Barcelona, Spain, 08035
- Hospital Universitari Vall d'Hebron
-
Ciudad Real, Spain, 13005
- Hospital General Universitario De Ciudad Real
-
Cáceres, Spain, 10003
- Hospital San Pedro de Alcántara
-
Donostia, Spain, 20014
- Hospital Universitario Donostia
-
Elche, Spain, 03203
- Hospital General Universitario de Elche
-
Galdakao, Spain, 48960
- Hospital de Galdakao
-
Gasteiz / Vitoria, Spain, 01009
- Hospital Universitario de Araba
-
Hospitalet de Llobregat, Spain, 08907
- Hospital Universitari de Bellvitge
-
Huelva, Spain, 21005
- Hospital Universitario Juan Ramon Jimenez
-
Lleida, Spain, 25198
- Hospital Universitari Arnau de Vilanova de Lleida
-
Lugo, Spain, 27003
- Hospital Universitario Lucus Agusti
-
Murcia, Spain, 30120
- Hospital Universitario Virgen Arrixaca
-
Málaga, Spain, 29010
- Hospital Universitario Virgen de la Victoria
-
Santander, Spain, 39008
- Hospital Universitario Marques de Valdecilla
-
Santiago De Compostela, Spain, 15706
- Hospital Clinico Universitario Santiago de Compostela
-
Valencia, Spain, 46010
- Hospital Clínico Universitario de Valencia
-
Zaragoza, Spain, 50009
- Hospital Clinico Universitario Lozano Blesa
-
-
Malaga
-
Málaga, Malaga, Spain, 29010
- Hospital Universitario Regional de Malaga Carlos Haya
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients with all inclusion criteria
Description
Inclusion Criteria:
- ≥18 years old
- PCI and stent implantation indication according to ESC Myocardial Revascularization Guidelines
- 1 or more stenosis at native coronary anatomy, in a 2-4mm vessel size, where 1 or more ihtDEStiny® drug eluting stent were implanted (or attempted to be implanted).
- Informed consent signed after PCI
Exclusion Criteria:
- Patient refusal to participate in the study
- Pregnancy
- Other DES implantation during index PCI, or 30 days before of after index PCI
- PCI at surgical grafts
- PCI for in-stent restenosis
- Killip class 3-4 Acute Coronary Syndromes (ACS)
- High bleeding risk with dual antiplatelet intolerance for at least 3 months (or 6 months for ACS PCI)
- Allergy or hypersensitivity to sirolimus
- Patients requiring surgery (cardiac or non-cardiac) in the next 3 months after index PCI
- Patients with life expectancy <2 years
- Patients included in other trials or clinical studies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Coronary Artery Disease
|
stenting with the ihtDEStiny® sirolimus eluting stent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Target Lesion Failure (TLF)
Time Frame: 2 years
|
Rate of target lesion failure
|
2 years
|
Death
Time Frame: 2 years
|
Death
|
2 years
|
Target vessel myocardial infarction
Time Frame: 2 years
|
Target vessel myocardial infarction
|
2 years
|
Target lesion revascularization (TLR)
Time Frame: 2 years
|
Target lesion revascularization (TLR)
|
2 years
|
Cardiovascular Death
Time Frame: 2 years
|
Cardiovascular Death
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stent thrombosis
Time Frame: 2 years
|
Stent thrombosis
|
2 years
|
Target Vessel Failure (TVF)
Time Frame: 2 years
|
Composite event of cardiovascular (CV) death, target vessel myocardial infarction (MI) and target vessel revascularization (TVR)
|
2 years
|
Major Adverse Cardiovascular Event (MACE)
Time Frame: 2 years
|
Composite event of cardiovascular (CV) death, non-fatal myocardial infarction (MI) and non-fatal stroke
|
2 years
|
Patient Oriented Composite Event
Time Frame: 2 years
|
Composite event of death, non-fatal myocardial infarction (MI), non-fatal stroke or any revascularization
|
2 years
|
Severe BARC Bleeding
Time Frame: 2 years
|
BARC Bleeding ≥3
|
2 years
|
Device success
Time Frame: During procedure
|
residual coronary stenosis<50%, normal coronary flow and absence of coronary dissection ≥C
|
During procedure
|
Procedural success
Time Frame: 3 days
|
Device success and absence of PCI complication (periprocedural MI, coronary perforation, urgent CABG or death) or revascularization within 3 days
|
3 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- de la Torre Hernandez JM, Ocaranza Sanchez R, Santas Alvarez M, Pinar Bermudez E, Hurtado Martinez JA, Garcia Del Blanco B, Otaegui I, Fernandez Nofrerias E, Carrillo Suarez X, Sainz Laso F, Casanova Sandoval JM, Rivera Aguilar PK, Cid B, Trillo R, Lozano Ruiz-Poveda F, Peral Disdier V, Telleria M, Torres A, Sanchis J, Oliva X, Freixa X, Sadaba Sagredo M, Moreu J, Hernandez F. Comparison of One-Year Outcomes Between the ihtDEStiny BD Stent and the Durable-Polymer Everolimus- and Zotarolimus-Eluting Stents: A Propensity-Score-Matched Analysis. Cardiovasc Revasc Med. 2021 Oct;31:1-6. doi: 10.1016/j.carrev.2020.09.046. Epub 2020 Oct 3.
- de la Torre Hernandez JM, Otaegui I, Subinas A, Gomez-Menchero A, Moreno R, Rondan J, Munoz-Garcia E, Sainz-Laso F, Garcia Del Blanco B, Rumoroso JR, Diaz JF, Berenguer A, Gomez-Lara J, Zueco J. First-in-Man Evaluation of a Sirolimus-Eluting Stent With Abluminal Fluoropolymeric/Triflusal Coating With Ultrathin Struts by OCT at 9 Months' Follow-Up: The PROMETHEUS Study. Cardiovasc Revasc Med. 2021 Nov;32:18-24. doi: 10.1016/j.carrev.2020.12.025. Epub 2020 Dec 29.
- Buiten RA, Ploumen EH, Zocca P, Doggen CJM, Danse PW, Schotborgh CE, Scholte M, van Houwelingen KG, Stoel MG, Hartmann M, Tjon Joe Gin RM, Somi S, Linssen GCM, Kok MM, von Birgelen C. Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT. JACC Cardiovasc Interv. 2019 Sep 9;12(17):1650-1660. doi: 10.1016/j.jcin.2019.04.054. Epub 2019 Aug 14.
- El-Hayek G, Bangalore S, Casso Dominguez A, Devireddy C, Jaber W, Kumar G, Mavromatis K, Tamis-Holland J, Samady H. Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents. JACC Cardiovasc Interv. 2017 Mar 13;10(5):462-473. doi: 10.1016/j.jcin.2016.12.002.
- Iantorno M, Lipinski MJ, Garcia-Garcia HM, Forrestal BJ, Rogers T, Gajanana D, Buchanan KD, Torguson R, Weintraub WS, Waksman R. Meta-Analysis of the Impact of Strut Thickness on Outcomes in Patients With Drug-Eluting Stents in a Coronary Artery. Am J Cardiol. 2018 Nov 15;122(10):1652-1660. doi: 10.1016/j.amjcard.2018.07.040. Epub 2018 Sep 8.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 29, 2021
Primary Completion (Actual)
April 1, 2023
Study Completion (Estimated)
April 1, 2025
Study Registration Dates
First Submitted
May 19, 2021
First Submitted That Met QC Criteria
May 19, 2021
First Posted (Actual)
May 24, 2021
Study Record Updates
Last Update Posted (Actual)
January 9, 2024
Last Update Submitted That Met QC Criteria
January 7, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPIC26-VELAZQUEZ
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on Percutaneous Coronary Intervention
-
Mid and South Essex NHS Foundation TrustImperial College LondonRecruitingStable Angina | Chronic Total Occlusion of Coronary ArteryUnited Kingdom
-
University Hospital, SaarlandCompletedAcute Myocardial InfarctionGermany
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedCoronary Artery DiseaseChina
-
University Hospital of PatrasCompletedCoronary Artery Bypass SurgeryGreece
-
Yonsei UniversityUnknownCoronary Artery Disease | Stable Angina | Unstable AnginaKorea, Republic of
-
ECRI bvBoston Scientific Corporation; Philips HealthcareActive, not recruitingLeft Main Coronary Artery StenosisSpain, United Kingdom, Italy
-
Herlev and Gentofte HospitalUnknownCoronary Heart Disease | Ischemic Heart Disease | Stable AnginaDenmark
-
RobocathCompletedCoronary Artery Disease | Percutaneous Coronary InterventionFrance, Belgium, Luxembourg, Netherlands
-
University College, LondonNational Institute for Cardiovascular Outcomes Research; British Cardiovascular... and other collaboratorsCompletedPercutaneous Coronary InterventionUnited Kingdom
-
Niels Ramsing HolmJohnson & JohnsonUnknown